

Heidelberg Pharma

ATACking cancer cells with novel technology

Heidelberg Pharma is building a proprietary pipeline of Antibody Targeted Amanitin Conjugates (ATACs). Lead product, HDP-101, is in preparation to start clinical development at the end of 2018. The company has a back-loaded research and option deal with Takeda that could be worth up to \$113m per product. The investment case rests on its current and new partnerships and on the clinical progress of its proprietary ATAC pipeline. Cash at end-9M17 was €4.5m; the company has an additional funding commitment of €5.6m, sufficient into Q218.

Combining ADC tech with a unique toxic payload

Heidelberg Pharma's ATAC technology combines the specificity of antibody drug conjugates (ADCs) with the toxin Amanitin. Preclinical data show that ATACs can eliminate active and dormant tumour cells, overcome resistance and prevent tumour relapse. Its lead product is HDP-101, which comprises a BCMA antibody and Amanitin, and has potential in multiple myeloma; preclinical studies have shown promising efficacy and tolerability in animal models. The company is conducting IND-enabling studies and aims to start clinical development in 2018. Furthermore, it is developing ATACs against CD19, PSMA and other targets in the early R&D stage.

Collaboration with Takeda provides early validation

Heidelberg Pharma has an exclusive research agreement with Takeda to generate ATACs using Takeda's proprietary antibody portfolio for up to three targets. Takeda has an option to in-license the products and potential milestone payments could be up to \$113m per product. Separately, during 9M17 the company out-licensed its diagnostic antibody Redectane to Telix, which will fund development and commercialisation. In return, Heidelberg Pharma is eligible to receive up to \$3.7m in upfront and milestone payments and royalties on global net sales.

Updated guidance for 2017 indicates funding to Q218

Heidelberg Pharma has adjusted its guidance for 2017. It now expects revenues in the range of €2-3m (vs €4-6m previously) due to deferred revenue from the Takeda deal and an EBIT loss of €9-11m (vs previous EBIT loss of €6-10m). The end-9M17 cash position was €4.5m. It has €5.6m available from a €10m financing commitment from dievini. It expects these funds to provide runway into Q218.

Valuation: Current enterprise value (EV) of €40m

Heidelberg's current EV is c €40m, which in our view reflects the early stage of its pipeline and alliances. Additional progress should unlock further value.

Consensus estimates

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/15	3.9	(6.6)	(0.8)	0.0	N/A	N/A
12/16	2.7	(6.4)	(0.5)	0.0	N/A	N/A
12/17e	3.5	(8.1)	(0.4)	0.0	N/A	N/A
12/18e	3.9	(9.7)	(0.4)	0.0	N/A	N/A

Source: Company (historics), Bloomberg consensus estimates

Pharma & biotech
15 November 2017

Price €2.66
Market cap €40m

Share price graph



Share details

Code WL6
 Shares in issue 14.97m
 Net cash (€m) as at end Q317 0.6

Business description

Heidelberg Pharma develops a proprietary pipeline of products based on the novel Antibody Targeted Amanitin Conjugates (ATAC). The lead product is HDP-101 in IND-enabling studies. The company has a collaboration agreement with Takeda potentially worth up to \$113m per product and deals for other assets: Redectane and Mesupron.

Bull

- Novel proprietary technology with a wide range of applications.
- Deal with Takeda provides initial validation.
- Potential upside from pipeline progression and additional partnerships.

Bear

- No clinical data yet.
- Early-stage pipeline and partnerships.
- Funding beyond Q218.

Analyst

Juan Pedro Serrate +44 (0)20 3681 2534

healthcare@edisongroup.com

EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") (c) FTSE [2014]. "FTSE(r)" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.